• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study.

作者信息

Ibba Luciano, Gargiulo Luigi, Alfano Angela, Cascio Ingurgio Ruggero, Narcisi Alessandra, Costanzo Antonio, Valenti Mario

机构信息

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

出版信息

J Dermatolog Treat. 2023 Dec;34(1):2199108. doi: 10.1080/09546634.2023.2199108.

DOI:10.1080/09546634.2023.2199108
PMID:37010456
Abstract
摘要

相似文献

1
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study.抗白细胞介素-23和抗白细胞介素-17药物治疗非脓疱型掌跖银屑病：一项真实世界回顾性研究
J Dermatolog Treat. 2023 Dec;34(1):2199108. doi: 10.1080/09546634.2023.2199108.
2
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study.白细胞介素-17和白细胞介素-23抑制剂对难治性银屑病区域（头皮、生殖器及掌跖部位）的临床疗效：一项回顾性、观察性、单中心、真实世界研究。
Expert Opin Biol Ther. 2023 Jul-Dec;23(9):929-936. doi: 10.1080/14712598.2023.2236023. Epub 2023 Jul 17.
3
Partial clinical response to anakinra in severe palmoplantar pustular psoriasis.阿那白滞素治疗严重掌跖脓疱性银屑病的部分临床反应。
Br J Dermatol. 2014 Sep;171(3):646-9. doi: 10.1111/bjd.13012. Epub 2014 Aug 7.
4
Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.托斯卡纳共识治疗中重度银屑病：更新和关注抗 IL-17 和抗 IL-23 生物制剂治疗中定位的实用指南。
Ital J Dermatol Venerol. 2022 Dec;157(6):469-479. doi: 10.23736/S2784-8671.22.07355-8. Epub 2022 Jul 5.
5
Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis.突出斑块状银屑病和脓疱型银屑病中的白细胞介素-36信号传导
Acta Derm Venereol. 2018 Jan 12;98(1):5-13. doi: 10.2340/00015555-2808.
6
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.掌跖脓疱型银屑病（PPPP）的特征是白细胞介素-17A通路的激活。
J Dermatol Sci. 2017 Jan;85(1):20-26. doi: 10.1016/j.jdermsci.2016.09.019. Epub 2016 Sep 29.
7
Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.靶向白细胞介素-17 和白细胞介素-23 的生物制剂治疗中重度斑块型银屑病的疗效和安全性：一项随机对照试验的系统评价和荟萃分析。
Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.
8
Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.掌跖脓疱型银屑病或掌跖脓疱病患者中白细胞介素-17A表达增加及白细胞介素-23参与有限；一项随机对照试验的结果
J Eur Acad Dermatol Venereol. 2014 Oct;28(10):1298-305. doi: 10.1111/jdv.12272. Epub 2013 Sep 24.
9
Biologics in the treatment of pustular psoriasis.生物制剂治疗脓疱型银屑病。
Expert Opin Drug Saf. 2020 Aug;19(8):969-980. doi: 10.1080/14740338.2020.1785427. Epub 2020 Jul 2.
10
Safety of biologics in psoriasis.生物制剂治疗银屑病的安全性。
J Dermatol. 2018 Mar;45(3):279-286. doi: 10.1111/1346-8138.14096. Epub 2017 Dec 10.

引用本文的文献

1
New-Onset Palmar Psoriasis Following mRNA COVID-19 Vaccination: A Case Report.新型冠状病毒 mRNA 疫苗接种后新发掌部银屑病：一例报告
Int Med Case Rep J. 2025 Aug 23;18:1085-1091. doi: 10.2147/IMCRJ.S535657. eCollection 2025.
2
Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning.用于中重度银屑病的布罗达单抗：疗效、安全性及临床定位的全面综述
Biologics. 2025 Jul 15;19:415-422. doi: 10.2147/BTT.S532526. eCollection 2025.
3
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis).
古塞库单抗在银屑病中的留存率、有效性及安全性：一项260周的真实世界多中心回顾性研究，探讨合并银屑病关节炎-白介素的银屑病（意大利银屑病情况）的作用
Dermatol Ther (Heidelb). 2025 Jul 3. doi: 10.1007/s13555-025-01476-1.
4
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).优化银屑病中替拉珠单抗的给药剂量：一项为期52周的多中心回顾性研究，比较100 mg和200 mg - IL PSO（意大利银屑病情况）
Dermatol Ther (Heidelb). 2025 Jun;15(6):1427-1440. doi: 10.1007/s13555-025-01416-z. Epub 2025 Apr 23.
5
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience.用于治疗斑块状银屑病的白细胞介素-17抑制剂类间的换药：单中心经验
Dermatol Reports. 2024 Nov 12. doi: 10.4081/dr.2024.10080.
6
Demographics, Disease Characteristics, and Treatment Patterns of Patients with Plaque Psoriasis Treated with Biological Drugs: The Experience of a Single-Centre Study in Poland.接受生物药物治疗的斑块状银屑病患者的人口统计学、疾病特征及治疗模式：波兰一项单中心研究的经验
J Clin Med. 2024 Dec 16;13(24):7647. doi: 10.3390/jcm13247647.
7
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).一项针对银屑病-IL PSO（意大利银屑病概况）部分缓解者从优特克单抗转换为古塞库单抗的3年多中心研究。
Dermatol Ther (Heidelb). 2024 Nov;14(11):2987-2997. doi: 10.1007/s13555-024-01270-5. Epub 2024 Oct 13.
8
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study.生物疗法治疗重度斑块状银屑病的有效性和安全性：一项真实世界回顾性研究
J Pers Med. 2024 Feb 7;14(2):186. doi: 10.3390/jpm14020186.
9
Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.依奇珠单抗治疗中重度斑块型银屑病（累及难治疗部位）的疗效：一项 52 周多中心回顾性研究。
J Dermatol. 2024 Jun;51(6):839-843. doi: 10.1111/1346-8138.17115. Epub 2024 Jan 31.
10
Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study.基于皮肤病生活质量指数评估的中国银屑病患者生活质量及其与疾病严重程度的相关性：一项横断面研究。
Ann Med. 2023 Dec;55(1):2231847. doi: 10.1080/07853890.2023.2231847.